These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29290171)

  • 1. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
    Parasuraman SV; Shi N; Paranagama DC; Bonafede M
    J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera.
    Komatsu N; Jun G; Yonezu T; Ohashi Y
    Int J Hematol; 2020 Aug; 112(2):176-184. PubMed ID: 32394272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
    Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
    J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
    Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
    Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
    MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
    J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
    Grunwald MR; Kuter DJ; Altomare I; Burke JM; Gerds AT; Walshauser MA; Savona MR; Stein B; Oh ST; Colucci P; Parasuraman S; Paranagama D; Mesa R
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):219-225. PubMed ID: 32063527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
    Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
    J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S; Duan R; Liu D; Reed BL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.